HEALTHCARE
INVESTMENT
POWERHOUSE

Peregrine offers our partners complete, end-to-end investment solutions to ensure the highest rate of success for groundbreaking healthcare-focused companies. Different stages of growth, require different levels of support, and in order to provide that support, Peregrine has created specifically defined funds.

INCUBATOR & PRE-SEED

INCUBATOR &
PRE-SEED

Peregrine’s ‘Incentive’ Incubator allows for investments in preseed companies where our team can help turn a creative idea into an innovative company. Through this vehicle, Peregrine provides our incubator companies with the technological infrastructure, financial management, business development support, strategic planning, and assistance in team recruitment that results in successful companies. In partnership with pharmaceutical multinational, Bristol-Myers Squibb (BMS) medical devices company, Becton Dickenson (BD) Israeli defense contractor, Elbit Systems and research institutes of Tel Aviv University, Ben-Gurion University of the Negev, and Shaare Zedek Medical Center,; the Incentive Incubator continues to be a leader in the medical technology sector.
EARLY & MID STAGE

EARLY &
MID STAGE

investingThe Peregrine Fund focuses on investments in early and mid-stage companies. In this vehicle, we work closely with entrepreneurs at the early-stage of business and product development, providing them with the tools and knowledge needed to take their company to the next level – from research and development to regulatory, reimbursement, and business operations.

GROWTH

GROWTH

The Peregrine Growth Fund seeks to assist more mature companies that have the potential to provide
outstanding returns withing a short time frame at low risk. Through deep industry connections, we help late-stage companies in their last rounds of financing prior to M&A or IPO. We understand the nuances of such a crucial business stage and our goal is to facilitate the transition
and allow companies to move on to the next stage in their lifecycle with confidence.